gogo
Amazon cover image
Image from Amazon.com

Industrialization of drug discovery : from target selection through lead optimization / edited by Jeffrey S. Handen.

Contributor(s): Material type: TextTextSeries: Drug discovery seriesPublication details: Boca Raton ; London : Taylor & Francis, 2005.Description: 305 p. : ill. ; 24 cmISBN:
  • 9780824723910 (alk. paper)
  • 9780824723910
Subject(s): DDC classification:
  • 615.19 HAN
LOC classification:
  • RM301.25 .I53 2005
Incomplete contents:
Chapter 1.Drug discovery in the modern age: how we got here and what does it mean? -- Chapter 2.The regulatory age -- Chapter 3.Industrialization, not automation -- Chapter 4.Compound management -- Chapter 5.High through-put screening -- Chapter 6.Parallel lead optimization -- Chapter 7.Knowledge management -- Chapter 8.Understanding the value of research -- Chapter 9.Collaboration in a virtual and global environment -- Chapter 10.From genome to drug: ethical issues.
Summary: In light of statistics and experience showing that drug discovery and development is getting longer, more expensive, and no better in the sense that the clinical attrition and safety-related market withdrawals today are about the same as they were 20 years ago contributors from pharmaceutical companies and some universities explore a new approach t.
Holdings
Item type Current library Call number Copy number Status Date due Barcode
Long Loan TUS: Midlands, Main Library Athlone General Lending 615.19 HAN (Browse shelf(Opens below)) 1 Available 201211

Includes bibliographical references and index.

Chapter 1.Drug discovery in the modern age: how we got here and what does it mean? -- Chapter 2.The regulatory age -- Chapter 3.Industrialization, not automation -- Chapter 4.Compound management -- Chapter 5.High through-put screening -- Chapter 6.Parallel lead optimization -- Chapter 7.Knowledge management -- Chapter 8.Understanding the value of research -- Chapter 9.Collaboration in a virtual and global environment -- Chapter 10.From genome to drug: ethical issues.

In light of statistics and experience showing that drug discovery and development is getting longer, more expensive, and no better in the sense that the clinical attrition and safety-related market withdrawals today are about the same as they were 20 years ago contributors from pharmaceutical companies and some universities explore a new approach t.

Powered by Koha